Patients receiving systemic treatment with any immunosuppressive medication (other than steroids as described above).
Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL- or anti-IL- receptor [IL-R])
Participants receiving systemic treatment with any immunosuppressive medication (other than steroids as described above)
Patients receiving systemic treatment with any immunosuppressive medication, excepting the above
Any condition requiring concurrent systemic immunosuppressive therapy
Chronic immunosuppressive therapy
Chronic immunosuppressive therapy
On stable immunosuppressive regimen for  weeks prior to enrollment; adjustment of immunosuppressive medications to maintain a therapeutic level is permitted
Patients must have received some immunosuppressive chemotherapy in the preceding  months.
Ongoing immunosuppressive therapy.
Treatment with systemic immunosuppressive medication within  weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study
Receiving immunosuppressive therapy including chronic steroids (except physiologic maintenance doses), methotrexate, or other known immunosuppressive agents
Ongoing treatment with immunosuppressive drugs
Regular immunosuppressive therapy
TREATMENT WITH SJCAR: Receiving systemic immunosuppressive therapy in the  days prior to CAR T-cell infusion
Systemic therapy with immunosuppressive agents within  days before enrollment
Treatment with systemic immunosuppressive medication;
Receiving immunosuppressive therapy
Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until  weeks after removal from immunosuppressive treatment
A requirement for systemic immunosuppressive therapy for any reason
Patients receiving concomitant immunosuppressive agents for medical condition
Has a history of the following immunosuppressive conditions: bone marrow transplantation, and/or organ transplants and/or chronic rheumatic conditions that require active immunosuppressive therapy; patients with chronic lymphoid/leukemic malignancies that have undergone treatment in the last  months will be ineligible
Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy
Immunosuppressive therapy within  days prior to the first dose of trial treatment
Patients must not be receiving active immunosuppressive therapy.
Patients receiving systemic treatment with any immunosuppressive medication.
Patients on immunosuppressive agents
Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agents
Patients on or requiring immunosuppressive therapies
Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until  weeks after removal from immunosuppressive treatment
Administration of immunosuppressive drugs less than  weeks prior to first dose of ERC
Systemic immunosuppressive therapy in the past  days
Patients must not be receiving active immunosuppressive therapy.
received immunosuppressive therapy <  months prior to study Day 
Systemic cytotoxic or immunosuppressive therapy to be administered concomitantly while participating on this study;
Need for ongoing treatment with an immunosuppressive agent
Is currently treated with systemic immunosuppressive agents, including steroids, are ineligible until  weeks after removal from immunosuppressive treatment
Patients on chronic steroid use or other immunosuppressive agents
Has a diagnosis of immunosuppressive disorder OR is on any other form of immunosuppressive therapy within  days prior to transplant admission
Any heart or lung transplant patient on immunosuppressive agents; renal transplant patients are allowed if patient is willing to reduce immunosuppressive agents and understand risk of rejection and possible need to return to dialysis; patients with chronic lymphocytic leukemia (CLL) or other hematologic malignancies are allowed
Patients who require systemic corticosteroid or other immunosuppressive therapy; immunosuppressive therapy must be stopped at least  days prior to cell infusion
A requirement for systemic immunosuppressive therapy for any reason
Patients needing chronic, immunosuppressive systemic steroids are excluded
Patients needing chronic, immunosuppressive systemic steroids are excluded
No change in systemic immunosuppressive therapy (type or intensity level) within  weeks prior to enrollment
Systemic immunosuppressive therapy for any reason
Expected need for regular immunosuppressive therapy
Active systemic immunosuppressive therapy
Concurrent immunosuppressive therapy and no known immunosuppressive disease other than primary tumour
Ongoing immunosuppressive therapy
Use of immune modulators and/or any immunosuppressive drugs.
Receiving immunosuppressive therapy
Immunosuppressive therapy
Use of systemic immunosuppressive drugs
Patients receiving chronic treatment with systemic steroids or another immunosuppressive agent.
Patients with known immunodeficiency or receiving immunosuppressive therapies
Patients receiving systemic treatment with any immunosuppressive medication.
Systemic immunosuppressive medication within  weeks prior to study drug
Patients on immunosuppressive therapy including:
No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for  weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug
No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for  weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug
Any condition requiring concurrent systemic immunosuppressive therapy
Immunosuppressive disease
A requirement for chronic systemic immunosuppressive therapy for any reason
Receiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edema
Patients must have no evidence of active graft-versus-host disease and must be on a stable immunosuppressive regimen (or no immunosuppressive medications) without a change in drugs dosage in the  weeks prior to the planned CD+ memory T cell infusion
Immunosuppressive agents (unless required for treating potential AEs)
Receiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edema
Chronic treatment with systemic steroids or another immunosuppressive agent
Patients on immunosuppressive drugs (with exception of corticosteroid)
Ongoing immunosuppressive therapy within  days prior to the start of study therapy;
use of immunosuppressive therapy, including systemic steroids within  days before the first dose of SG.
Receiving immunosuppressive drugs
Patients requiring continuous, systemic immunosuppressive therapy
Chronic treatment with systemic steroids or another immunosuppressive agent
Need for ongoing treatment with an immunosuppressive agent.
Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until  weeks after removal from immunosuppressive treatment
Clinically uncontrolled autoimmune disorders, transplant recipients who depend on immunosuppressive therapy, other immunosuppressive conditions including any concurrent condition requiring immunosuppressive/immunomodulating agents;
Use of any systemic immunosuppressive agents
On immunosuppressive therapy.
Receiving immunosuppressive therapy
Subjects with conditions requiring chronic steroid or immunosuppressive treatment
Chronic treatment with systemic steroids or another immunosuppressive agent
Immunosuppressive therapy within the last  months
Patients on immunosuppressive drugs (with exception of corticosteroid)
Subjects with immunosuppressive disease that require use of systemic steroids or immunosuppressive treatment
immunodeficiency, immune compromised state or receiving immunosuppressive therapy
No addition or subtraction of other immunosuppressive medications (e.g., calcineurin inhibitors, sirolimus, mycophenolate mofetil) for  weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug
No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for  weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug
Patients on chronic immunosuppressive medications, including steroids, within the past three months
No addition or subtraction of other immunosuppressive medications (e.g., calcineurin inhibitors, sirolimus, mycophenolate mofetil) for  weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug
Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agents
Need for chronic immunosuppressive drugs
Need for chronic immunosuppressive drugs
Patients who take immunosuppressive medication, i.e. steroid therapy or other immunosuppressive/immunomodulating drugs (e.g. Cyclosporine) within  months prior to first study drug injection
Is taking immunosuppressive therapy
Chronic immunosuppressive therapy within  days of screening
Confirmed or suspected immunosuppressive or immunodeficient condition
Treatment with systemic immunosuppressive medication
Receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate
Are immunosuppressed or in chronic use of immunosuppressive drugs.
ongoing chronic immunosuppressive therapy
The participant is receiving therapy with immunosuppressive agents.
The participant is receiving therapy with immunosuppressive agents.
